PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28744453-3	2017	Sorafenib is a treatment of choice for patients with performance status 1 or 2 and/or macrovascular invasion or extrahepatic spread, and regorafenib is the only systemic treatment found to provide survival benefit in HCC patients progressing on sorafenib treatment.	regorafenib	137-148	HCC	Homo sapiens	217-220	
28437801-0	2017	[Regorafenib - a revolution in the systemic treatment options of HCC?]	regorafenib	1-12	HCC	Homo sapiens	65-69